P&G DIDROCAL PROSPECTIVE STUDY IN HIGH FRACTURE RISK OSTEOPOROSIS PATIENTS NEEDED, FDA CMTE. CONCLUDES; WIDESPREAD OFF-LABEL USE REPORTED
Executive Summary
Proctor & Gamble's osteoporosis treatment Didrocal needs positive efficacy data from a prospective clinical study in high-risk populations, FDA's Endocrinologic & Metabolic Drugs Advisory Committee indicated in its second evaluation of the bisphosphonate drug.